Navigation Links
Isis Initates Phase 2/3 Study Of ISIS-TTR Rx And Earns $7.5 Million Milestone Payment From GlaxoSmithKline
Date:2/19/2013

S-TTRRx on neurological dysfunction and on quality-of-life.  The United States Food and Drug administration granted ISIS-TTRRx fast track designation and orphan drug status for the treatment of FAP.

"The rapid development of ISIS-TTRRx from a research-stage program to a drug in late-stage clinical development in just over two years represents the strong commitment of both teams to bring this novel drug to patients who are in need of new therapeutic options," said B. Lynne Parshall , chief operating officer at Isis.  "The encouraging data from our Phase 1 study, in which our drug was well tolerated and produced significant reductions in TTR protein, supported the advancement of ISIS-TTRRx directly into this registration-directed Phase 2/3 study.  While we will continue to manage the clinical development of ISIS-TTRRx, we will benefit from GSK's late-stage clinical development, regulatory and commercial expertise."

ISIS-TTRRx is part of the Isis-GSK strategic alliance to develop RNA therapeutics for rare and infectious diseases.  For the initiation of the Phase 2/3 study, Isis will receive a $7.5 million milestone payment and is eligible to earn an additional $50 million in pre-licensing milestone payments to support the Phase 2/3 study of ISIS-TTRRx­.  In addition, Isis is eligible to receive regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx.

ABOUT ISIS-TTRRx
Transthyretin amyloidosis is a genetic disease in which the patient inherits a mutant gene that produces a misfolded form of TTR, which progressively accumulates in tissues, impairing their function.  In patients with transthyretin amyloidosis, both the mutant and normal forms of TTR can build up as fibrils in tissues, including heart, peripheral nerves, and the gastrointestinal tract.&
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Edison Pharmaceuticals & Bambino Gesu Childrens Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial
2. Neurim Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of Piromelatine for the Treatment of Insomnia
3. NW Bio Takes Next Steps In Moving Forward With Its Phase III Brain Cancer Trial In Europe
4. Ferring to Highlight Phase 3 Data for Cervical Ripening Candidate at Society for Maternal-Fetal Medicine Annual Meeting
5. RNL BIO filed Phase II/III Clinical Trial with KFDA to Treat Cerebral Palsy Using Autologous Fat Derived Stem Cells
6. Lilly Discontinues Phase 3 Rheumatoid Arthritis Program for Tabalumab Based on Efficacy Results
7. Matrixx Initiatives Withdraws Acquisition Offer for ProPhase Labs
8. Cytos VLP Platform is Basis for Phase 1 Clinical Trial with Anti-IgE Vaccine
9. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
10. Targovax AS Announces First Patient Included in Phase I/II Clinical Study With the Therapeutic Cancer Vaccine TG01 in Operable Pancreatic Cancer
11. Cell Therapeutics Announces Data Safety and Monitoring Board Recommendation to Continue the GOG-0212 Phase 3 Clinical Trial of OPAXIOTM as Maintenance Therapy in Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)...  Pifflers United Chronic and Invisible Illnesses Support ... results of a study of ActiPatch®, a new ... fibromyalgia pain. The results demonstrated that when used ... clinically meaningful pain reduction can be achieved. ... used ActiPatch® for 7 days and were then ...
(Date:11/23/2014)... DAYTON, N.J. , Nov. 23, 2014  Aurobindo ... lot GESB14011-A of Gabapentin Capsules, USP 300 mg 100-count ... been found to contain some empty capsules. ... resulting in adverse health consequences that could range from ... withdrawal effect, or status epilepticus (long period seizures) that ...
(Date:11/22/2014)... Nov. 21, 2014  CytoSorbents Corporation (OTCQB: CTSO), ... Union approved CytoSorb® cytokine adsorber to treat critically-ill ... Beacon of Light Award at last night,s New ... Dr. Phillip Chan , Chief Executive ... to be recognized by the New Jersey Tech ...
Breaking Medicine Technology:Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 3Aurobindo Pharma USA, Inc. Issues Voluntary Nationwide Recall of Northstar Label Gabapentin Capsules, USP 300 mg Due to Complaints of Empty Capsules 2CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4
(Date:11/24/2014)... Volpara Solutions announced today that it ... Annual Meeting of the Radiology Society of North ... 1752 – South Hall). Volpara Solutions will showcase ... of its innovative suite of quantitative breast imaging ... measurements of volumetric density, patient-specific dose, breast compression ...
(Date:11/24/2014)... Recently, SweetDressy.com, a well-known dress supplier and leader in ... Evening Dresses. All these fresh items are offered at ... the special offer is valid until Dec. 20, 2014. ... been working well in the fashion industry for years. ... new dresses may be the best products for many ...
(Date:11/24/2014)... 2014 SafeHandles™ announced that they will ... Ed Begley Jr, airing via Discovery Channel. Dates and ... a passive, non-invasive, replaceable, and affordable germ protective device. ... shrinkable sleeves and adhesives to promote hand hygiene in ... core of SafeHandles is the desire to make a ...
(Date:11/23/2014)... The clinical trial report, "Aspergillosis ... on the Aspergillosis clinical trial scenario. This report ... clinical trials on Aspergillosis. It includes an overview ... as per the site of trial conduction across ... of disease clinical trials by their phase, trial ...
(Date:11/23/2014)... Pro Ace Care, a renowned Vancouver hot water tank company, ... 8 year warranty on its selected hot water tanks. As ... to the impending winter season, it was important for Pro ... that the company provides. As a result, Pro Ace will ... Bradford hot water tanks. , “Every installer who works ...
Breaking Medicine News(10 mins):Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:SweetDressy.com Unveiled A New Selection Of Evening Dresses 2Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2
... people who are unlikely to incur high medical expenses. ... families, finds a study of Massachusetts families from Children,s ... Care and Prevention (DACP). The study appears in the ... The researchers, led by Alison Galbraith, MD, MPH, and ...
... survive severe injuries on battlefields such as those in ... infections of their wounds with multidrug resistant bacteria. The ... Staphylococcus aureus (MRSA), Acinetobacter baumannii , ... coli . , Dr Clinton K. Murray, from Brooke ...
... to create open access to information that will enhance ... ORLANDO, Fla., March 29 /PRNewswire/ -- ... GE Healthcare,s Cardiovascular Ultrasound unit announced a formal affiliation ... an integrated solution aimed at improving workflow for echocardiography ...
... allergen breathed in by a person with asthma triggers a ... events to prompt an allergic reaction, said a consortium of ... in Houston in a report that appears online today in ... activates interleukin 25, a key mediator of the allergic response ...
... Relaxin cuts shortness of breath and trimmed hospital stays, phase ... The hormone relaxin reduces shortness of breath and cardiovascular death ... pressure, according to a phase 2 trial conducted in eight ... a few hours of arriving at a hospital, were randomly ...
... Doctor urges first responders to clean equipment regularly ... News) -- One in three stethoscopes used by ... methicillin-resistant Staphylococcus aureus (MRSA) bacteria, a new study ... and Dentistry of New Jersey swabbed 50 stethoscopes ...
Cached Medicine News:Health News:Low-income families with sick children often enrolled in high-deductible health care plans 2Health News:ProSolv CardioVascular and GE Healthcare Ultrasound Division Announce Affiliation 2Health News:ProSolv CardioVascular and GE Healthcare Ultrasound Division Announce Affiliation 3Health News:Hormone Reduces Mortality in Heart Patients With High BP 2Health News:Third of EMS Stethoscopes Carry MRSA Bacterium 2
Inquire...
Inquire...
Inquire...
... a range of 18 Ophthalmic frames ... and producted to the very hightest ... super lightweight Titanium and Beta Titanium ... host of beautifully formed and innovative ...
Medicine Products: